---
title: Telcagepant for Prevention of Menstrually Related  | PMS & PMDD trial
description: Completed. Clinical trial on Migraine run by Merck Sharp & Dohme LLC.
url: https://niyora.com/research/trials/telcagepant-for-prevention-of-menstrually-related-migraine-nct01125774/
---

- [Niyora](https://niyora.com/)
- [Research](https://niyora.com/research/)
- [Clinical trials](https://niyora.com/research/trials/)
- Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

Completed

# Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine

Status Completed Registry ID NCT01125774 Type Interventional (tests a treatment) Phase Phase 2, Phase 3 Conditions Migraine What is tested Telcagepant (drug); Placebo (drug) Sponsor Merck Sharp & Dohme LLC Participants 4548 Start 2010-06-01 Completion 2011-04-08 Last update 2018-10-23 Results posted Yes

## About the study

This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period. This study will also evaluate the safety and tolerability of telcagepant for female migraine participants.

Summary from ClinicalTrials.gov.

[See the full record](https://clinicaltrials.gov/study/NCT01125774)

Ask AI about this page

Copy prompt

ChatGPT

↗

Claude

↗

Perplexity

↗

Google AI Mode

↗

Grok

↗